Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ: NTLA )

9.200 -0.020 (-0.22%)
Streaming Delayed Price Updated: 10:58 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
There's more than one reason to sell a stock while buying another. 
Via The Motley Fool
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money.
One of these stocks has already doubled this year. 
Via The Motley Fool
Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.
It has quite a few of the core ingredients for success in biopharma. 
Via The Motley Fool
Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy
Success could be in the DNA of the Ark Invest founder. 
Via The Motley Fool
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
What 10 Analyst Ratings Have To Say About Intellia Therapeutics
Via Benzinga
Where Intellia Therapeutics Stands With Analysts
Via Benzinga
Why Is Intellia (NTLA) Stock Up 5% Today?
NTLA stock is trending on social media and is up over 5%. The drugmaker reported new, positive results from its gene-edited treatment. 
Via InvestorPlace
Can This Gene-Editing Stock Deliver 10X Returns?
Buying shares of Intellia Therapeutics might be a smart move. 
Via The Motley Fool
3 Cathie Wood Investments That Could Deliver Superior Returns
These three stocks fit Wood's profile for big-time growth. 
Via The Motley Fool
2 Short-Squeeze Candidates That Could Go Parabolic
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
2 Growth Stocks Cathie Wood Is Buying Hand Over Fist
The fund manager most famous for innovation-focused investing thinks these two stocks have what it takes to produce big gains. 
Via The Motley Fool
Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst
Sunday, Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated interim results from the Phase 1 portion of the ongoing  
Via Benzinga
Why Are Cruise Stocks CCL, RCL, NCLH Up Today?
Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details! 
Via InvestorPlace
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing
Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday. 
Via InvestorPlace
12 Analysts Have This to Say About Intellia Therapeutics
Via Benzinga
Intellia Therapeutics: Q1 Earnings Insights
Via Benzinga
Intellia Therapeutics's Earnings Outlook
Via Benzinga
Intellia Therapeutics Surges As CRISPR Gene-Editing Drug Potentially Cures Swelling Disease
The company is testing a treatment for hereditary angioedemia, a potentially fatal swelling disorder. 
Via Investor's Business Daily
Why Intellia Therapeutics Stock Is Rising Monday
Intellia Therapeutics Inc (NASDAQ: NTLA) shares are trading higher Monday after the clinical-stage genome editing company announced data for its treatment for people living with hereditary angioedema... 
Via Benzinga
Chinook Therapeutics, Oracle And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. Chinook Therapeutics, Inc. (NASDAQ: KDNY) shares jumped 66.8% to $40.01 in... 
Via Benzinga
Wall Street Says These 2 Stocks May Double. Should You Buy Them?
Both of these stocks have declined over the past year. 
Via The Motley Fool
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
The Ark Invest CEO is betting on rebounds for these beaten-down stocks. 
Via The Motley Fool
Why Intellia Therapeutics Shares Are Surging Today
Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares are up Thursday as its Q1 results surpassed estimates. The company looks forward to sharing new interim data from NTLA-2001 and NTLA-2002... 
Via Benzinga
The 3 Most Promising Gene Editing Stocks to Buy in 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor has stumbled after a hot start to 2023, but Wood keeps adding to some of her favorite positions. 
Via The Motley Fool
3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat
Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat. 
Via InvestorPlace
3 High-Growth Biotech Stocks Poised for Success in 2023
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
2 Monster Growth Stocks That Can Double in Value, According to Wall Street
These stocks have some promising growth opportunities, but they also come with a fair amount of risk. 
Via The Motley Fool
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.